Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVA237 Phase 2 Dose-Ranging Study in COPD
NCT00501852Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2007
- Primary completion
- Dec 2007
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of glycopyrronium in chronic obstructive pulmonary disease (COPD), sponsored by Novartis. Started Jul 2007; status: completed.
02
Drugs
glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00501852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00501852.